New report: Parkinson’s costs community
A new report released by Parkinson’s Australia this week has found that Parkinson’s is costing the community $10 billion every year.
Written by Deloitte Access Economics, Living with Parkinson’s Disease: An updated economic analysis 2014, highlights the significant growth in health system costs, productivity loss, and the financial burden for people living with Parkinson’s.
Released in Parliament House on Tuesday, the key findings of the Deloitte Access Economics report include:
- Parkinson's costs the Australian community almost $10 billion each year. This figure has almost doubled since 2005.
- Since 2005, there's been an increase of 103 percent in direct financial costs of Parkinson's ($1.1 billion) and an increase of 42 percent ($8.9 billion) in the burden of disease.
- Parkinson's remains one of the most prevalent neurodegenerative conditions in Australia. Nearly 70,000 people in Australia are living with Parkinson's - a dramatic increase of 27 percent in just nine years.
- More than 11,500 people are diagnosed with Parkinson's every year.
- It is estimated that by 2034, more than 123,000 people will be living with Parkinson’s.
Positive steps for the future
The new report outlines cost effective interventions to assist people living with Parkinson's to achieve a better quality of life, while simultaneously reducing the cost of this condition to the community. It also provides practical strategies for reducing direct health care costs. This includes avoiding unnecessary hospital and aged care admissions, and decreasing lengths of stay and medical specialist consultations.
To reduce the costs of Parkinson's to the community, Parkinson's Australia - the national peak body representing the needs of people living with Parkinson’s, their families and carers - is advocating for the Federal and state governments to commit to a National Action Plan. This plan will include:
- Recognition of Parkinson’s as a National Health Priority Area;
- Investment in better care and support for people living with Parkinson’s through access to Parkinson’s Nurse Specialists and equitable access to medications and therapies;
- Investment in upskilling the workforce to enable timely diagnosis, better care and support of people living with Parkinson’s; and
- Investment and capacity building in Parkinson’s research.
Read the full Deloitte Access Economics report.